Medicine and HealthTranslational Lung Cancer Research
LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
Z. He, W. Feng, et al.
This groundbreaking study reveals that LRP1B mutations in lung adenocarcinoma patients can enhance their response to immune checkpoint inhibitors, leading to better clinical outcomes. Conducted by Ziyi He and colleagues from the Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, this research showcases LRP1B mutation as a promising prognostic biomarker.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Human cytomegalovirus in breast milk is associated with milk composition and the infant gut microbiome and growth
K. E. Johnson, N. Hernandez-alvarado, et al.
Psychology
Bed-Sharing in Couples Is Associated With Increased and Stabilized REM Sleep and Sleep-Stage Synchronization
H. J. Drews, S. Wallot, et al.
Veterinary Science
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
B. A. Alsaihati, K. Ho, et al.
Medicine and Health
Cardiotoxicity Associated with Immune Checkpoint Inhibitors
S. Minegishi, N. Horita, et al.
